BioSpace News Archive

An updated analysis shows further improvement of progression-free survival, disease control rate and objective response rate in the cohort of FGFR2 gene fusion-positive patients with bile duct cancer (iCCA) in FIDES-01 study

Noema Pharma AG, a Swiss clinical-stage company targeting orphan neurological disorders, announces it will attend several investor conferences during June and July.

RhoVac AB, a Swedish cancer immunotherapy company, announces , May 31, 2021, that it confirms its previous forecast to be able to conclude recruitment for its multi-centre BRaVac Phase IIb study in Quarter 3 2021.

WhiteLab Genomics, specialist in artificial intelligence (AI) dedicated to gene and cell therapies, is entering into a collaboration with ART-TG, Inserm laboratory expert in the preclinical and pharmaceutical development of ex vivo gene therapies.

Quotient Limited, a commercial-stage diagnostics company, announced the management team will participate in two upcoming investor conferences.

PENTAX Medical and Jiangsu Vedkang Medical Science and Technology Co., Ltd announced the establishment of a joint venture- PENTAX Medical Therapeutics Co., Ltd. to develop single-use therapeutics products in the field of flexible medical endoscopy.

AIDS Healthcare Foundation, the world’s largest provider of HIV/AIDS care globally, calls on the World Health Assembly and world leaders to do everything necessary to conduct an entirely new and independent investigation into the origins of the novel coronavirus.

MedX Health Corp. announced its results for the three-months ended March 31, 2021, which are also available on SEDAR.

Innovent Biologics, Inc. and AnHeart Therapeutics Co., Ltd. jointly announce an exclusive license agreement for the co-development and commercialization of AnHeart’s lead drug candidate, taletrectinib – a next-generation tyrosine kinase inhibitor designed to effectively target ROS1 and NTRK - in Greater China, including mainland China, Hong Kong, Macau and Taiwan.

Baudax Bio, Inc. announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 14,028,520 shares of common stock and warrants to purchase up to an aggregate of 14,028,520 shares of common stock at a purchase price of $0.85 per share and accompanying warrant in a registered direct offering.